8-K: Oragenics Enters At-the-Market Sales Agreement for Up to $10 Million in Common Stock

Oragenics, Inc. has entered into an at-the-market sales agreement with Dawson James Securities to potentially sell up to $10 million of its common stock.

Summary

• Oragenics, Inc. has signed an At-the-Market Sales Agreement with Dawson James Securities, allowing the company to sell shares of its common stock over time.
• The company may issue and sell shares depending on market demand, with Dawson James acting as the sales agent or principal.
• Sales can be made through various methods, including directly on the NYSE American.
• Oragenics is not obligated to sell any shares and can suspend sales if prices are not favorable.
• Dawson James will receive a commission of up to 3.0% of the gross proceeds from the sale of shares.
• Oragenics will also reimburse Dawson James for legal fees, up to $30,000 initially and $2,500 per quarter.
• The offering is made under an existing registration statement, with a prospectus supplement filed on October 11, 2024, for an aggregate offering price of $10,000,000.
• The company intends to use the net proceeds to fund the development of its ONP-002 product candidate and for general corporate purposes and working capital.
• The timing and amount of proceeds used will depend on research and development progress, funding needs, and the availability of other funds.

Sentiment

Score: 6

Explanation: The document is neutral to slightly positive. It outlines a standard capital-raising activity, which is necessary for the company's operations and development. However, it also introduces potential dilution and costs.

Positives

• The at-the-market offering provides Oragenics with a flexible way to raise capital.
• The funds raised will support the development of the ONP-002 product candidate.
• The agreement allows the company to sell shares based on market conditions, potentially maximizing proceeds.
• The company has the option to suspend sales if the price is not favorable.

Negatives

• The company will incur commission costs of up to 3.0% on the gross proceeds from the sale of shares.
• There are additional legal fees to be paid to Dawson James' counsel.
• The company's stock price could be diluted by the issuance of new shares.
• The precise amount and timing of the application of proceeds is dependent on a number of factors.

Risks

• The company's ability to sell shares is dependent on market demand.
• The company may not be able to sell all of the shares at the desired price.
• The company's stock price could be negatively impacted by the offering.
• The development of ONP-002 is subject to risks and uncertainties.

Future Outlook

The company intends to use the net proceeds from the offering to fund the continued development of its ONP-002 product candidate and for general corporate purposes and working capital. The precise amount and timing of the application of these proceeds will depend upon a number of factors.

Industry Context

At-the-market offerings are a common method for companies, particularly in the biotech sector, to raise capital. This allows them to take advantage of market conditions and raise funds as needed without a large, dilutive offering.

Comparison to Industry Standards

• The commission rate of up to 3.0% is within the typical range for at-the-market offerings.
• The legal fee reimbursement structure is also standard for these types of agreements.
• Many biotech companies use at-the-market offerings to fund research and development, similar to Oragenics' stated use of proceeds.
• Comparable companies that have used at-the-market offerings include XOMA Corporation and Agenus Inc.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares.
• Employees may benefit from the continued funding of the company's operations and development.
• Customers may benefit from the development of new products.
• Creditors may be impacted by the company's increased debt or equity.

Next Steps

• Oragenics will begin selling shares through Dawson James Securities based on market conditions.
• The company will file additional prospectus supplements if it decides to offer more than $10 million in shares.
• The company will use the net proceeds to fund the development of its ONP-002 product candidate and for general corporate purposes and working capital.

Key Dates

Keywords

at-the-market offering, common stock, capital raise, Dawson James Securities, ONP-002, securities, Oragenics, sales agreement, prospectus supplement